ReviewVascular health and risk management2010
New standards in hypertension and cardiovascular risk management: focus on telmisartan.
Review in Vascular health and risk management, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 53 citations in OpenAlex.
- Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT.Hypertension (Dallas, Tex. : 1979) · 2026Trial
- Bioequivalence and Food Effect Assessment of Two Fixed-Dose Combination Formulations of Telmisartan-Hydrochlorothiazide Tablets in Chinese Healthy Subjects.Clinical and translational science · 2025Trial
- Sustained blood pressure-lowering effect of aliskiren compared with telmisartan after a single missed dose.Journal of clinical hypertension (Greenwich, Conn.) · 2013Trial
- Telmisartan ameliorates reproductive dysfunction, oxidative stress, and mitochondrial damages induced by fipronil in male rats via regulation of Nrf2/HO-1/PGC-1α/MNF2/DRP1.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Decoding Drug Interactions: Character and Degree of Pharmacokinetic Interactions Between Telmisartan and Sorafenib or Donafenib in Rats.Drug design, development and therapy · 2025Article
- Atrial fibrillation in heart failure patients: An update on renin-angiotensin-aldosterone system pathway blockade as a therapeutic and prevention target.Cardiology journal · 2023Article
- Telmisartan detection by UV spectrophotometry in mice drinking water.Analytical science advances · 2021Article
- Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study.PLoS medicine · 2021Article
- Hot-Melt Extruded Amorphous Solid Dispersion for Solubility, Stability, and Bioavailability Enhancement of Telmisartan.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Review
- Efficacy and tolerability of telmisartan plus amlodipine in asian patients not adequately controlled on either monotherapy or on low-dose combination therapy.International journal of hypertension · 2014Article
- Changes of gene expressions in spontaneously hypertensive rat model after losartan treatment.Korean circulation journal · 2012Article
- What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?Cardiovascular diabetology · 2012Review
- Metabolic effect of combined telmisartan and nifedipine CR therapy in patients with essential hypertension.International journal of general medicine · 2012Article
- Review
- Effect of telmisartan on blood pressure in patients of type 2 diabetes with or without complications.Perspectives in clinical researchArticle
- Improving hypertension control in patients at cardiovascular risk: the case for telmisartan-based therapy.Cardiovascular journal of AfricaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blockade of the renin-angiotensin system is an important approach in managing high blood pressure, and has increasingly been shown to affect cardiovascular disease processes mediated by angiotensin II throughout the cardiovascular and renal continua. Telmisartan is an angiotensin II receptor blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure. In patients with mild-to-moderate hypertension, telmisartan has proved superior to other antihypertensive agents (valsartan, losartan, ramipril, perindopril, and atenolol) in controlling blood pressure particularly towards the end of the dosing interval. There is also clinical evidence that telmisartan reduces left ventricular hypertrophy, reduces arterial stiffness and the recurrence of atrial fibrillation, and confers renoprotection. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) study has demonstrated that telmisartan has similar cardiovascular protective effects to ramipril in a large, high-risk patient population but was better tolerated. The powerful and sustained blood pressure control apparent in clinical trials, together with cardiovascular protection and tolerability demonstrated in ONTARGET means that telmisartan may be a preferred option for patients with hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.